|
 |
|
 |
国際個別化医療学会誌
国際個別化医療学会誌
原著
Retrospective analysis of clinical responses in patients with gastroenterological cancer treated with dendritic cell vaccine
Retrospective analysis of clinical responses in patients with gastroenterological cancer treated with dendritic cell vaccine
Shinichiro Akiyama1, Kozo Hamaya1, Yoshinori Ito1,Hiroyasu Yasuda2, Minako Abe1, Hiroyuki Abe1
1Kudan Clinic
2Department of Clinical Application, Translational Research Center, Tohoku University
2Department of Clinical Application, Translational Research Center, Tohoku University
Objectives: Tumor-specific cytotoxic T lymphocytes (CTLs) can be efficiently activated in vivo by dendritic cell (DC)-based vaccination. We’ve already reported that neither WT-1 nor MUC1 pulsed DC vaccination can elicit strong immune response so as to exhibit anti-tumor effects. In the current study, we have evaluated the clinical responses in the patients with advanced gastroenterological carcinoma, who received DC-based immunotherapy.
Methods: DC-based immunotherapy (DC vaccine alone or DC vaccine plus lymphokine-activated killer cell therapy) has been carried out in the 59 patients with inoperable gastroenterological carcinoma refractory to standard treatment. DCs which were generated from CD14+ monocytes from leukapheresis by 6-day cultivation with GM-CSF and IL-4, then were matured by OK-432 and pulsed with the cancer-associated antigens, such as WT-1, MUC1. Synergistic DCs were administered intradermally more than 5 times at 14-day intervals.
Results: Of 59 patients, 0 patients showed CR, 12 PR and 13 SD. None of the patient experienced adverse events of grade 2 or higher during the treatment period. Response ratio was 20.3％, control ratio was 42.4％.
Conclusion: In the current study, it has been strongly suggested that DC vaccine-based immunotherapy might be safe and effective in the patients with advanced gastroenterological carcinoma refractory to standard treatment.
Methods: DC-based immunotherapy (DC vaccine alone or DC vaccine plus lymphokine-activated killer cell therapy) has been carried out in the 59 patients with inoperable gastroenterological carcinoma refractory to standard treatment. DCs which were generated from CD14+ monocytes from leukapheresis by 6-day cultivation with GM-CSF and IL-4, then were matured by OK-432 and pulsed with the cancer-associated antigens, such as WT-1, MUC1. Synergistic DCs were administered intradermally more than 5 times at 14-day intervals.
Results: Of 59 patients, 0 patients showed CR, 12 PR and 13 SD. None of the patient experienced adverse events of grade 2 or higher during the treatment period. Response ratio was 20.3％, control ratio was 42.4％.
Conclusion: In the current study, it has been strongly suggested that DC vaccine-based immunotherapy might be safe and effective in the patients with advanced gastroenterological carcinoma refractory to standard treatment.
■Key words：gastroenterological carcinoma, dendritic cell vaccine, esophageal carcinoma, gastric carcinoma, colorectal carcinoma, pancreas carcinoma
■連絡先 Kudan Clinic, Shinko Bldg 6F, 1-11-4 Kudan-kita, Chiyoda-ku, Tokyo 102-0073, Japan E-mail: akiyama@kudanclinic.com
Tel: 03-3263-0511 Fax: 03-5210-7311
■連絡先 Kudan Clinic, Shinko Bldg 6F, 1-11-4 Kudan-kita, Chiyoda-ku, Tokyo 102-0073, Japan E-mail: akiyama@kudanclinic.com
Tel: 03-3263-0511 Fax: 03-5210-7311
